XTX Topco Ltd Raises Stake in Editas Medicine, Inc. (NASDAQ:EDIT)

XTX Topco Ltd increased its stake in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 352.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 475,381 shares of the company's stock after purchasing an additional 370,325 shares during the period. XTX Topco Ltd owned 0.57% of Editas Medicine worth $551,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of EDIT. Allspring Global Investments Holdings LLC boosted its stake in shares of Editas Medicine by 45.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 35,781 shares of the company's stock valued at $40,000 after purchasing an additional 11,252 shares during the last quarter. Brave Asset Management Inc. lifted its holdings in Editas Medicine by 250.0% in the first quarter. Brave Asset Management Inc. now owns 35,000 shares of the company's stock valued at $41,000 after buying an additional 25,000 shares during the period. Dark Forest Capital Management LP boosted its stake in Editas Medicine by 66.9% in the fourth quarter. Dark Forest Capital Management LP now owns 32,787 shares of the company's stock valued at $42,000 after acquiring an additional 13,138 shares during the last quarter. Freestone Grove Partners LP acquired a new stake in Editas Medicine during the 4th quarter worth $46,000. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of Editas Medicine by 144.4% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 45,017 shares of the company's stock valued at $52,000 after acquiring an additional 26,601 shares during the last quarter. Institutional investors own 71.90% of the company's stock.

Editas Medicine Price Performance

Shares of Editas Medicine stock traded down $0.04 on Thursday, hitting $2.49. 873,793 shares of the company's stock traded hands, compared to its average volume of 2,259,801. The company has a fifty day moving average of $2.47 and a two-hundred day moving average of $1.81. Editas Medicine, Inc. has a one year low of $0.91 and a one year high of $4.44. The company has a market capitalization of $208.44 million, a price-to-earnings ratio of -0.82 and a beta of 2.19.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.51) by $0.08. The firm had revenue of $4.66 million for the quarter, compared to analysts' expectations of $0.79 million. Editas Medicine had a negative return on equity of 139.24% and a negative net margin of 701.06%. During the same period in the prior year, the business earned ($76.00) EPS. Equities research analysts anticipate that Editas Medicine, Inc. will post -2.71 earnings per share for the current year.

Insider Buying and Selling at Editas Medicine

In related news, CEO Gilmore Neil O'neill sold 15,192 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $1.72, for a total value of $26,130.24. Following the sale, the chief executive officer owned 280,282 shares in the company, valued at $482,085.04. This represents a 5.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 21,485 shares of company stock worth $40,897 over the last quarter. 2.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Robert W. Baird cut their target price on Editas Medicine from $8.00 to $4.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Cantor Fitzgerald raised Editas Medicine from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 29th. Wall Street Zen raised shares of Editas Medicine from a "sell" rating to a "hold" rating in a research note on Saturday, July 26th. Finally, HC Wainwright started coverage on shares of Editas Medicine in a research note on Monday, April 28th. They issued a "buy" rating and a $3.00 target price for the company. Two analysts have rated the stock with a sell rating, eight have given a hold rating, two have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Editas Medicine presently has an average rating of "Hold" and an average target price of $4.70.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.